CFN Media Group announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.
InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) announced today that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for the scale-up, purification, and manufacturing strategies for InMed’s cannabinoid biosynthesis program.
iAnthus Capital Holdings, Inc., (CSE: IAN) (CSE: IAN.CN) (CNSX: IAN) (OTCQB: ITHUF), announces the appointment of Carlos Perea as Chief Operating Officer. Mr. Perea's hire adds another highly experienced member to iAnthus' expert operations team
Emerald Health Therapeutics Inc. (EHT) (TSXV:EMH) (OCTQX:EMHTF) today announced that its wholly owned subsidiary, Emerald Health Botanicals Inc., has completed a purchase of dried cannabis from Supreme Pharmaceuticals Inc.’s (TSXV:FIRE) subsidiary, 7ACRES.
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program.
As part of the ongoing Hurricane Irma relief efforts, Diamond CBD will be donating 10 percent of all net proceeds for the next three days and offering a 50 percent discount storewide.
Front Range Biosciences announces it has raised $3 million in bridge round funding.
Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) announced today that it has received all the required permits to ship dried cannabis flower from Canada to Germany.
Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX), through wholly-owned subsidiary CBD Biotechnology Co. Ltd., this morning announced that it has completed the record filing process with the China Food & Drug Administration (“CFDA”) for its first line of non-industrial hemp-infused skin care products.
ABcann Global receives $11.9 Million from the exercise of outstanding warrants.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has received total proceeds of nearly $11.9 million from the exercise of an aggregate of 19,185,965 warrants since the closing of its acquisition of ABcann Medicinals Inc. on April 28, 2017.
ABcann Global receives $11.9 Million from the exercise of outstanding warrants.
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model.
he Green Organic Dutchman Holdings Ltd. announces the syndicate for the offering of 4,242,500 Units of the Company at a price of C$1.65 per Unit for aggregate gross proceeds of C$7,000,125.
StockHouse did an in-depth look at InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) about their model, technology and the "Big Picture"
